proved that c-Myc is the convergent downstream effector of multiple major signaling pathways including MAPK/ERK, PI3K/Akt, Notch1, and Yes-associated protein, that is both necessary and sufficient for BRAFi resistance in melanoma patients. The gene discussed is MYC; the disease is melanoma.